Risk factors for treatment failure in scabies: a cohort study.
Administration, Cutaneous
Administration, Oral
Adolescent
Adult
Animals
Antiparasitic Agents
/ administration & dosage
Beds
/ parasitology
Benzoates
/ administration & dosage
Child
Child, Preschool
Cohort Studies
Decontamination
Drug Administration Schedule
Drug Therapy, Combination
/ methods
Female
France
Humans
Infant
Ivermectin
/ administration & dosage
Male
Risk Assessment
Risk Factors
Sarcoptes scabiei
/ drug effects
Scabies
/ drug therapy
Treatment Failure
Young Adult
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
accepted:
21
10
2018
pubmed:
31
10
2018
medline:
6
5
2020
entrez:
31
10
2018
Statut:
ppublish
Résumé
Treatment failure, which occurs in about one-third of cases, is considered as a major factor in the increasing incidence of scabies in developed countries. To identify predictors of treatment failure of scabies in ambulatory populations. This multicentre study compared the clinical characteristics and treatment modalities between a group of patients with scabies treated successfully and another group who were not cured 3 months after antiscabies treatment. In total 210 patients with a diagnosis of scabies were included, comprising 98 patients in the treatment success group and 112 in the treatment failure group. The main risk factors for treatment failure were (i) the use of only one type of treatment, topical benzyl benzoate (BB) or oral ivermectin, vs. the combination of both treatments [odds ratio (OR) 2·15, 95% confidence interval (CI) 1·22-3·77]; (ii) the use of a single intake (vs. two) of oral ivermectin (OR 10·2. 95% CI 4·49-23·2); (iii) intake of ivermectin during a meal vs. on an empty stomach (OR 4·31, 95% CI 1·89-9·84); (iv) absence of decontamination of furnishings (OR 8·72, 95% CI 3·50-21·8), in particular sofa and cushions (OR 5·90, 95% CI 2·34-14·9), mattresses (OR 4·16, 95% CI 1·35-12·8) or car seats (OR 6·57, 95% CI 3·27-13·2) and (v) absence of written documents explaining treatment modalities (OR 5·18, 95% CI 2·57-10·4). In multivariate analysis, treatment failure was mainly associated with (i) use of a single intake (vs. two) of ivermectin (OR 6·62, 95% CI 2·71-16·2); (ii) use of BB alone vs. two intakes of ivermectin (OR 3·51, 95% CI 1·55-7·95) and (iii) absence of decontamination of furniture with acaricides (OR 5·81, 95% CI 1·96-16·7). Use of topical BB alone and a single intake (vs. two) of ivermectin are predictors of treatment failure.
Sections du résumé
BACKGROUND
Treatment failure, which occurs in about one-third of cases, is considered as a major factor in the increasing incidence of scabies in developed countries.
OBJECTIVES
To identify predictors of treatment failure of scabies in ambulatory populations.
METHODS
This multicentre study compared the clinical characteristics and treatment modalities between a group of patients with scabies treated successfully and another group who were not cured 3 months after antiscabies treatment.
RESULTS
In total 210 patients with a diagnosis of scabies were included, comprising 98 patients in the treatment success group and 112 in the treatment failure group. The main risk factors for treatment failure were (i) the use of only one type of treatment, topical benzyl benzoate (BB) or oral ivermectin, vs. the combination of both treatments [odds ratio (OR) 2·15, 95% confidence interval (CI) 1·22-3·77]; (ii) the use of a single intake (vs. two) of oral ivermectin (OR 10·2. 95% CI 4·49-23·2); (iii) intake of ivermectin during a meal vs. on an empty stomach (OR 4·31, 95% CI 1·89-9·84); (iv) absence of decontamination of furnishings (OR 8·72, 95% CI 3·50-21·8), in particular sofa and cushions (OR 5·90, 95% CI 2·34-14·9), mattresses (OR 4·16, 95% CI 1·35-12·8) or car seats (OR 6·57, 95% CI 3·27-13·2) and (v) absence of written documents explaining treatment modalities (OR 5·18, 95% CI 2·57-10·4). In multivariate analysis, treatment failure was mainly associated with (i) use of a single intake (vs. two) of ivermectin (OR 6·62, 95% CI 2·71-16·2); (ii) use of BB alone vs. two intakes of ivermectin (OR 3·51, 95% CI 1·55-7·95) and (iii) absence of decontamination of furniture with acaricides (OR 5·81, 95% CI 1·96-16·7).
CONCLUSIONS
Use of topical BB alone and a single intake (vs. two) of ivermectin are predictors of treatment failure.
Substances chimiques
Antiparasitic Agents
0
Benzoates
0
Ivermectin
70288-86-7
benzyl benzoate
N863NB338G
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
888-893Investigateurs
S Bechu
(S)
N Mion-Mouton
(N)
O Lafaurie
(O)
A Barrel
(A)
M Pulluard
(M)
V Hamel
(V)
M X Dore
(MX)
E Duflo
(E)
S Lardans-Cassius
(S)
J C Rzeznik
(JC)
S Baricault
(S)
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2018 British Association of Dermatologists.